skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Nifedipine represses ion channels, transporters and Ca{sup 2+}-binding proteins in hearts of spontaneously hypertensive rats

Journal Article · · Toxicology and Applied Pharmacology
 [1];  [1]
  1. Fraunhofer Institute of Toxicology and Experimental Medicine, Drug Research and Clinical Inhalation, Nicolai-Fuchs-Str. 1, D-30625 Hannover (Germany)

The Ca{sup 2+} antagonists nifedipine has been used for more than three decades to treat hypertension, but its effects on the transcriptional regulation of cardiac genes are basically unknown. We therefore studied expression of genes coding for ion channels, ion transporters and associated partners as well as Ca{sup 2+}-binding proteins in ventricular tissue of normotensive and spontaneously hypertensive (SH) rats after repeated intraperitoneally (i.p.) dosing of nifedipine. Notably, we observed significant (P < 0.05) repression in transcript levels of most of the genes investigated, including cardiac Na{sup +}, K{sup +}, Ca{sup 2+}-channels (L-type Ca{sup 2+}-channel, K{sub ir}3.4, K{sub ir}6.1, Na{sub v}1.5), ATP-driven ion exchangers (Na{sup +}-K{sup +}-ATPase, NCX-1, PMCA 2 and 4, SERCA 2a and 2b) and their associated partners (phospholamban, RyR-2) as well as cytoskeletal proteins ({alpha} and {beta}-MHC, {alpha} cardiac and {alpha} skeletal actin, troponin T and I). Repression in transcript levels was, however, only seen in ventricular tissue of hypertensive animals. This points to fundamental differences in the mode of action of nifedipine in diseased and healthy animals. Indeed, this preponderance of repressed genes will promote disturbed ion homeostasis to result in contractile dysfunction. It is of considerable importance that repressed gene expression was also seen in end-stage human heart failure [Borlak, J., Thum, T., 2003. Hallmarks of ion channel gene expression in end-stage heart failure. FASEB J. 17, 1592-1608]. We propose repression of cardiac-specific gene expression as a hallmark of nifedipine treatment in hypertrophic hearts.

OSTI ID:
20850345
Journal Information:
Toxicology and Applied Pharmacology, Vol. 213, Issue 3; Other Information: DOI: 10.1016/j.taap.2005.10.012; PII: S0041-008X(05)00621-6; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0041-008X
Country of Publication:
United States
Language:
English